

ASAC TRIAL

Scandinavian Livermet Study


NEWSLETTER

- December 2021

Covid-19 and Inclusion

We hope everyone are doing well. Although we were hoping for a better 2021, It's still special time, and the pandemic has affected the number of included patients, illustrated in the figure below.

Despite the low inclusion rate, we are optimistic, and want to thank you for your work and encourage you to keep on including all eligible patients. We have now included 452 patients in the study.



Study medication

Batch # XB1901 expires 31.03.2022. We want to use as much of this batch as possible, so Cecilie Moe has been allocating KIT-nr., and she will continue to allocate until you have received study medication from the new batch.

For all those who have not received medication from the new batch, Cecilie will contact you. If you have any questions regarding allocation, please contact Cecilie Moe at cecimoe@ous-hf.no/+47-41541987.

When it comes to the new batch, the SN on the respective site will allocate for each patient. You will receive more information regarding this pr. Email.

If the sites have study medicine after expire date, please destruct it according to local policy. If patients have extra study medicine after reaching the study endpoint, please ask them to bring it to their local pharmacy for destruction.

Adverse Events

Lastly, we would like to ask all of you to please fill out the eCRF in VieDoc continuously.

Please do not hesitate to contact us if you have any questions! We are available on phone and e-mail.

We would like to wish you all a Merry Christmas and a happy new year! -The ASAC team
www.asac.no



